Pacific Biosciences of California, Inc. PACB
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 159.27M | 160.03M | 160.01M | 154.58M | 156.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 159.27M | 160.03M | 160.01M | 154.58M | 156.11M |
| Cost of Revenue | 112.41M | 111.10M | 117.55M | 108.61M | 113.09M |
| Gross Profit | 46.86M | 48.93M | 42.45M | 45.97M | 43.02M |
| SG&A Expenses | 131.40M | 134.18M | 143.19M | 163.48M | 176.13M |
| Depreciation & Amortization | 4.06M | 4.06M | 10.14M | 15.97M | 21.80M |
| Other Operating Expenses | 4.18M | 4.20M | 8.27M | 5.09M | 5.09M |
| Total Operating Expenses | 341.00M | 342.00M | 377.06M | 400.95M | 426.58M |
| Operating Income | -181.73M | -181.97M | -217.05M | -246.37M | -270.47M |
| Income Before Tax | -130.56M | -127.77M | -546.06M | -503.20M | -526.31M |
| Income Tax Expenses | 827.00K | 804.00K | 318.00K | 432.00K | 49.00K |
| Earnings from Continuing Operations | -131.39 | -128.58 | -546.38 | -503.63 | -526.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.39M | -128.58M | -546.38M | -503.63M | -526.36M |
| EBIT | -181.73M | -181.97M | -217.05M | -246.37M | -270.47M |
| EBITDA | -167.42M | -167.84M | 165.38M | 142.01M | 125.47M |
| EPS Basic | -0.43 | -0.43 | -1.84 | -1.69 | -1.79 |
| Normalized Basic EPS | -0.36 | -0.36 | -0.43 | -0.52 | -0.57 |
| EPS Diluted | -0.44 | -0.43 | -1.84 | -1.70 | -1.79 |
| Normalized Diluted EPS | -0.36 | -0.36 | -0.43 | -0.50 | -0.56 |
| Average Basic Shares Outstanding | 1.22B | 1.21B | 1.20B | 1.18B | 1.15B |
| Average Diluted Shares Outstanding | 1.22B | 1.21B | 1.20B | 1.20B | 1.18B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |